Table 1.
Clinicopathologic Characteristics of the MDACC Discovery Cohort (n=73)
| Total | Basal | p53-like | Luminal | p-value | |
|---|---|---|---|---|---|
| Cohort Size | 73 | 23 (32%) | 26 (36%) | 24 (33%) | |
| Mean Age (y) ± SD | 68.8 ± 10.2 | 70.1 ± 9.4 | 69.8 ± 8.9 | 66.4 ± 12.1 | 0.371 |
| Gender | |||||
| Female | 19 (26%) | 10 (44%) | 6 (23%) | 3 (13%) | 0.133 |
| Male | 54 (74%) | 13 (57%) | 20 (77%) | 21 (88%) | |
| Race | |||||
| Caucasian | 54 (74%) | 14 (61%) | 21 (81%) | 19 (79%) | |
| African American | 12 (16%) | 6 (26%) | 2 (7%) | 4 (17%) | 0.352 |
| Hispanic | 7 (10%) | 3 (13%) | 3 (12%) | 1 (4%) | |
| Clinical Stage at TUR (N0, M0) | |||||
| ≤ cT1 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| cT2 | 37 (51%) | 9 (39%) | 16 (62%) | 12 (50%) | 0.990 |
| cT3 | 16 (22%) | 4 (17%) | 7 (27%) | 5 (21%) | |
| cT4 | 6 (8%) | 2 (9%) | 2 (8%) | 2 (8%) | |
| Positive Clinical Lymph Nodes, cN+ | 11 (15%) | 5 (22%) | 1 (4%) | 5 (21%) | 0.137 |
| Positive Clinical Metastasis, cM+ | 7 (10%) | 5 (22%) | 0 (0%) | 2 (8%) | 0.035 |
| Primary Treatment | |||||
| Cystectomy | 57 (78%) | 15 (65%) | 25 (96%) | 17 (71%) | 0.019 |
| Other* | 16 (22%) | 8 (35%) | 1 (4%) | 7 (29%) | |
| Neoadjuvant Chemotherapy, NAC | 18 (25%) | 5 (22%) | 7 (27%) | 6 (25%) | 0.910 |
| Response to NAC^ | |||||
| Yes | 6 (33%) | 2 (40%) | 0 (0%) | 4 (67%) | 0.018 |
| No | 12 (67%) | 3 (60%) | 7 (100%) | 2 (33%) | |
| Pathologic T stage (n=57) | |||||
| pT0 | 4 (7%) | 2 (13%) | 0 (0%) | 2 (12%) | |
| pTa, pT1, pTis | 6 (11%) | 2 (13%) | 1 (4%) | 3 (18%) | |
| pT2 | 10 (18%) | 1 (7%) | 4 (16%) | 5 (29%) | 0.001 |
| pT3 | 25 (44%) | 4 (27%) | 18 (72%) | 3 (18%) | |
| pT4 | 12 (21%) | 6 (40%) | 2 (8%) | 4 (22%) | |
| Positive Pathologic Lymph Nodes | 23 (40%) | 3 (13%) | 14 (54%) | 6 (25%) | 0.010 |
| Variant histology in specimen | |||||
| Squamous Differentiation | 18 (32%) | 13 (57%) | 4 (15%) | 1 (4%) | |
| Sarcomatoid Differentiation | 3 (5%) | 3 (13%) | 0 (0%) | 0 (0%) | <0.001 |
| Other (Micropapillary, Glandular, Adenocarcinoma) | 3 (5%) | 0 (0%) | 3 (12%) | 0 (0%) | |
| Median Overall Survival (m) | 37.2 | 14.9 | 34.6 | 65.6 | 0.098 |
| Median Disease Specific Survival (m) | 46.3 | 14.9 | Not Reached | 65.6 | 0.028 |
Other= Chemotherapy was recommended for all 16 patients, based on available medical records 9 patients had documentation of completion
Response to NAC= Decrease in stage to pT0 or pT1 (for patients with high risk features at TUR: lymphovascular invasion, variant histology, hydronephrosis, or abnormal exam under anesthesia) at cystectomy.
The Kruskal-Wallis test was used to compare differences in mean age between groups. Log-rank test was used to compare differences in survival (overall and disease specific) between groups. For the remainder of categorical variables, Fisher’s exact test was used to determine differences between subtypes. p-values <0.05 were considered significant.